Today on Drug Discovery & Development
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
Q&A: Keys to unlock data science potential for drug discovery
Drug Discovery and Development See More >
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
The RCSB Protein Data Bank has announced that more than 1,000 SARS-CoV-2 proteins are available at no cost. Headquartered at Rutgers University–New Brunswick, the RCSB Protein Data Bank released its first SARS-CoV-2 structure — the coronavirus main protease (PDB 6lu7) — on Feb. 5, 2020. The database has helped drive the development of effective COVID-19 vaccines. It continues to shed…
Sponsored Content See More >
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
The RCSB Protein Data Bank has announced that more than 1,000 SARS-CoV-2 proteins are available at no cost. Headquartered at Rutgers University–New Brunswick, the RCSB Protein Data Bank released its first SARS-CoV-2 structure — the coronavirus main protease (PDB 6lu7) — on Feb. 5, 2020. The database has helped drive the development of effective COVID-19 vaccines. It continues to shed…
Infectious Disease See More >
Study finds AstraZeneca COVID-19 vaccine could be effective against Brazil variant
Early data from a University of Oxford study indicates the COVID-19 vaccine it jointly developed with AstraZeneca is effective against the P.1 variant, which originated in Brazil. The study has not yet been published, but Reuters confirmed its results. South Africa recently paused the vaccine rollout, where a similar variant is circulating after early study data indicated…
Oncology See More >
Q&A: Why IMV’s DPX-Survivac shows promise in treating ovarian cancer
The biopharmaceutical company IMV (NSDQ:IMV) has recently revealed promising data related to its lead immunotherapy as a potential ovarian cancer treatment. In the Phase 2 DeCidE1 trial, the immunotherapy DPX-Survivac with intermittent low-dose cyclophosphamide showed durable anti-tumor activity in patients with recurrent, advanced ovarian cancer. A recent analysis from three different clinical trials published in published…
